Kaplan and Sadocks Comprehensive Textbook of Psychiatry, 11e



33.7 Serotonin Antagonists/Inverse Agonists

33.11b Cholinesterase Inhibitors and Memantine



Samir A. Sabbag, M.D., Zelde Espinel, M.D., M.P.H., Luminita Luca, M.D., Ph.D., and Elizabeth A. Crocco, M.D.

33.7a Pimavanserin

3215 Joan M. Striebel, M.D., Jennifer A. O’Day, M.D., Nekisa Haghighat, M.D., M.P.H., and Stephen M. Stahl, M.D., Ph.D., D.Sc. (Hon.)

33.12 Histamine Modulators


33.8 Noradrenaline Modulators


33.12a Histamine Blockers and Enhancers

33.8a α 2 -Adrenergic Receptor


Sasson Zemach, M.D., and Abraham Weizman, M.D.

Agonists: Clonidine, Clonidine Extended Release, Guanfacine, and Guanfacine Extended Release

33.13 Pharmacological Treatments of Substance Abuse



Eric Hollander, M.D., and Migena Dervishi, M.D. 33.8b β -Adrenergic Receptor Antagonists

33.13a Opioid Receptor Modulators

3350 33.13a.1 Opioid Maintenance Treatments: Methadone and Buprenorphine ��� 3350


Migena Dervishi, M.D., and Eric Hollander, M.D.

33.9 GABA Enhancers


Jonathan R. Buchholz, M.D., Kelly Barth, D.O., and Andrew J. Saxon, M.D.

33.9a Barbiturates and Similarly Acting Substances Steven L. Dubovsky, M.D., and Dori Marshall, M.D. 33.9b Benzodiazepine Receptor Agonists and Antagonists


33.13a.2 Opioid Receptor Antagonists: Naltrexone and Nalmefene



Steven L. Dubovsky, M.D., and Dori Marshall, M.D. 33.10 Cation Function Modulators and Lithium (“Mood Stabilizers”)

Oluwole O. Jegede, M.D., M.P.H., Stephanie S. O’Malley, Ph.D.,

3256 33.10a Calcium Channel Inhibitors ��� 3256 Steven L. Dubovsky, M.D., and Dori Marshall, M.D. 33.10b Gabapentin, Topiramate, Tiagabine, Levetiracetam, Zonisamide, and Pregabalin ��� 3264 Hiroyuki Uchida, M.D., Ph.D. 33.10c Carbamazepine 3277 Robert M. Post, M.D., and Mark A. Frye, M.D. 33.10d Lamotrigine 3295 Robert M. Post, M.D. 33.10e Valproate 3300 Robert M. Post, M.D., and Mark A. Frye, M.D. 33.10f Lithium 3313 Robert H. Belmaker, M.D.

Tiffany Arnold, B.S., M.D., Katherine S. Pier, M.D., and Srinivas B. Muvvala, M.D., M.P.H. 33.13b Disulfiram and Acamprosate ��� 3367 Katherine S. Pier, M.D. 33.14 Fast-Acting Pharmacologic Treatments 3378 33.14a Esketamine and Ketamine 3378 Carlos A. Zarate, Jr., M.D., and Lawrence T. Park, A.M., M.D. 33.14b MDMA, Psilocybin, Ayahuasca, and Ibogaine 3386 David Nutt, F.R.C.P., F.R.C.Psych.,

F.B.Ph.S., F.Med.Sci., D.Laws., and David Erritzoe, M.D., Ph.D., M.R.C.Psych.

33.15 Hormone Receptor Enhancers


33.15a Melatonin Receptor Agonists

33.11 Acetylcholine Blockers and Enhancers



Tawny L. Smith, Pharm.D., B.C.P.P., and D. Jeffrey Newport, M.D., M.S., M.Div.

33.11a Anticholinergics and Amantadine


Copyright © 2025 Wolters Kluwer, Inc. Unauthorized reproduction of this content is prohibited. Samoon Ahmad, M.D.

Made with FlippingBook - professional solution for displaying marketing and sales documents online